Supreme Court Case on Fish Oil Drug Could Impact Generic Drug Prices

The Supreme Court of the United States is set to hear a case that could affect how quickly lower-cost generic drugs reach patients. The dispute, known as Hikma v. Amarin, involves Hikma Pharmaceuticals and Amarin over a heart disease drug called Vascepa.

At the centre of the case is a practice called “skinny labeling.” This allows generic drugmakers to sell cheaper versions of medicines for uses that are no longer protected by patents, even if other uses of the same drug remain protected. This pathway has helped bring lower-cost drugs to market faster and has saved billions in healthcare costs.

Amarin sued Hikma after it launched a generic version of Vascepa in 2020, arguing that Hikma encouraged doctors to prescribe the drug for uses that were still under patent. Hikma maintains that its actions followed standard marketing and labeling practices. While a lower court ruled in Amarin’s favour, the Supreme Court has agreed to review the decision.

The outcome of the case could have significant implications. If the Court sides with Amarin, generic companies may face higher legal risks when using skinny labeling, potentially delaying the introduction of cheaper medicines. This could lead to longer periods of higher drug prices for patients.

On the other hand, if Hikma prevails, the current system may remain largely unchanged, allowing generics to enter the market more quickly. Experts say the decision could shape the balance between encouraging innovation and ensuring access to affordable medicines.